Avalyn Pharma (NASDAQ:AVLN) Stock: Insider Fmr Llc Sells 53,454 Shares

Avalyn Pharma Inc. (NASDAQ:AVLN) insider Fmr Llc sold 53,454 shares of the stock in a transaction that occurred on Tuesday, November 10th. The shares were sold at an average price of $30.21, for a total transaction of $1,614,845.34. Following the transaction, the insider owned 2,056,081 shares in the company, valued at approximately $62,114,207.01. This trade represents a 2.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Fmr Llc also recently made the following trade(s):

• On Monday, November 9th, Fmr Llc sold 175,000 shares of Avalyn Pharma stock. The stock was sold at an average price of $29.07, for a total transaction of $5,087,250.00.

Avalyn Pharma Trading Down 1.0%

NASDAQ:AVLN opened at $30.28 on Friday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 33.12 and a current ratio of 33.12. Avalyn Pharma Inc. has a 12 month low of $22.24 and a 12 month high of $40.17. The company has a market cap of $1.34 billion and a P/E ratio of -1.33. The stock has a 50 day moving average of $28.66.

Avalyn Pharma (NASDAQ:AVLN) last announced its earnings results on Thursday, November 12th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.03). Research analysts forecast that Avalyn Pharma Inc. will post -3.86 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages recently commented on AVLN. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Avalyn Pharma in a report on Wednesday. Raymond James Financial assumed coverage on Avalyn Pharma in a report on Friday, October 2nd. They issued an “outperform” rating and a $60.00 target price on the stock. Wall Street Zen raised Avalyn Pharma from a “sell” rating to a “hold” rating in a report on Saturday. Finally, Morgan Stanley raised their target price on Avalyn Pharma from $53.00 to $57.00 and gave the stock an “overweight” rating in a research report on Thursday, August 13th. Two analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Avalyn Pharma presently has a consensus rating of “Moderate Buy” and a consensus price target of $60.00.

Institutional Trading of Avalyn Pharma

Several large investors have recently added to or reduced their stakes in the business. State Street Corp grew its position in Avalyn Pharma by 73.7% during the third quarter. State Street Corp now owns 554,004 shares of the company’s stock valued at $15,784,000 after buying an additional 235,009 shares during the period. Profund Advisors LLC purchased a new stake in Avalyn Pharma during the third quarter valued at approximately $668,000. China Universal Asset Management Co. Ltd. bought a new position in Avalyn Pharma in the third quarter worth approximately $29,000. Manchester Capital Management LLC bought a new position in Avalyn Pharma in the third quarter worth approximately $36,000. Finally, Braidwell LP bought a new position in Avalyn Pharma in the second quarter worth approximately $26,382,000.

About Avalyn Pharma

Avalyn Pharma is a clinical-stage biopharmaceutical company developing inhaled treatments for pulmonary fibrosis, including idiopathic pulmonary fibrosis and other progressive fibrotic lung diseases. Its approach is designed to deliver medicine directly to the lungs. The company’s pipeline includes AP01, an investigational inhaled formulation of pirfenidone, and AP02, an investigational inhaled formulation of nintedanib. Both medicines are based on drugs used in oral form for pulmonary fibrosis, but Avalyn’s inhaled candidates are being studied as potential alternatives to oral treatment.